Nativis is a Seattle-based clinical stage therapeutic device company whose patented, groundbreaking technology utilizes precisely targeted, ultra-low radio frequency energy (ulRFE®) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive investigational device. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of health-related needs. Nativis’ initial focus is on the treatment of patients with brain cancer (initially, glioblastoma), with additional pre-clinical work being undertaken for lung and other cancers, inflammatory disease and chronic pain.

Authors

Chris Rivera

President, Chief Executive Officer and Chairman of Nativis, Inc.

Rivera has more than 30 years of experience in the biotechnology industry. He was founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma; and Senior Vice President at both Terc...

❮ ❯

Articles

3058

Nativis’ platform aims to transform disease trea...